Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2021-11-01 AGM Information
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
BioArctic presenterar valberedningen
AGM Information Classification · 1% confidence The document is a press release ("Pressmeddelande") from BioArctic AB announcing the composition of its Nomination Committee ("valberedningen") ahead of the 2022 Annual General Meeting (AGM). The text details which major shareholders appointed representatives to this committee, which is responsible for proposing board members, remuneration, and the AGM chairman. This content directly relates to the governance and preparation for the AGM, specifically concerning the nomination process. This aligns best with 'AGM Information' (AGM-R), as it is material directly related to the upcoming shareholder meeting process, even though it is not the final proxy statement or the meeting minutes themselves. It is more specific than a general Regulatory Filing (RNS) or Governance Information (CGR).
2021-11-01 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT' and covers the period 'July – September 2021'. It contains comprehensive financial summaries, including income statements, cash flow data, and key financial performance indicators for both the quarter and the year-to-date period. It also includes management commentary (CEO comments), operational updates, and a project portfolio overview. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2021
2021-10-21 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period July–September 2021. It contains comprehensive financial summaries, including income statements, cash flow data, and key financial ratios for both the quarter and the year-to-date period. It also includes a CEO statement, business strategy, and a detailed project portfolio. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2021
2021-10-21 Swedish
Eisai påbörjar stegvis inlämning av ansökan till FDA för lecanemab vid tidig Alzheimers sjukdom, genom ett accelererat förfarande för marknadsgodkännande
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces that Eisai has initiated a 'rolling Biologics License Application' (BLA) to the FDA for lecanemab. It details clinical trial results (Phase 2b, ongoing Phase 3 Clarity AD) and mentions the accelerated approval pathway. This is a public announcement regarding significant regulatory and clinical progress for a drug candidate, issued by BioArctic AB. This type of announcement, which is not a full financial report (10-K, IR) or a transcript (CT), but rather a specific corporate update concerning regulatory filings and development milestones, fits best under the general category of Regulatory Filings (RNS) or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the format and content focusing on regulatory submission progress, RNS is the most appropriate general regulatory announcement category, as it is not explicitly covered by other specific codes like DIV, CAP, or MANG. Since it is a press release detailing regulatory submission progress, RNS (Regulatory Filings) serves as the best fit among the provided options for a non-financial, non-meeting specific corporate update.
2021-09-28 Swedish
Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces that Eisai has initiated a rolling submission of a Biologics License Application (BLA) to the US FDA for lecanemab. This is an announcement regarding regulatory progress and clinical trial data, not the final comprehensive annual report (10-K), a quarterly report (IR), or a formal earnings release (ER). Since it is a specific announcement about regulatory action (BLA submission) and clinical data related to a drug candidate, it fits best under the general category of Regulatory Filings (RNS) as it is a broad regulatory update that doesn't fit the more specific financial report codes. However, given the context of drug development and regulatory submissions, it is a significant corporate announcement. It is not a standard financial filing like 10-K or IR. It is a press release detailing regulatory progress. RNS is the most appropriate fallback for significant, non-standard regulatory/corporate news that isn't explicitly covered by other codes like DIV, CAP, or MANG. It is not a Report Publication Announcement (RPA) because it is announcing the *submission* of an application, not the publication of a completed report like an Annual Report or an Investor Presentation.
2021-09-28 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT' and covers the period 'April – June 2021'. It contains comprehensive financial summaries, including net revenues, operating profit, cash flow, and key financial performance indicators for the specified period. It also includes management commentary from the CEO and detailed operational updates. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2021
2021-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.